midodrine has been researched along with Hepatitis C in 2 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure." | 6.69 | Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999) |
| " Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure." | 2.69 | Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Olivera-Martinez, M | 1 |
| Martinez, MO | 1 |
| Sayles, H | 1 |
| Vivekanandan, R | 1 |
| D' Souza, S | 1 |
| Florescu, MC | 1 |
| Angeli, P | 1 |
| Volpin, R | 1 |
| Gerunda, G | 1 |
| Craighero, R | 1 |
| Roner, P | 1 |
| Merenda, R | 1 |
| Amodio, P | 1 |
| Sticca, A | 1 |
| Caregaro, L | 1 |
| Maffei-Faccioli, A | 1 |
| Gatta, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355] | Phase 4 | 29 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis
| Intervention | participants (Number) |
|---|---|
| Albumin (Control Group) | 2 |
| Vasoconstrictor (Treatment Group) | 2 |
Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days
| Intervention | days (Median) |
|---|---|
| Albumin (Control Group) | 10 |
| Vasoconstrictor (Treatment Group) | 8 |
1 trial available for midodrine and Hepatitis C
| Article | Year |
|---|---|
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Topics: Aldosterone; Ascites; Blood Pressure; Diuresis; Electrolytes; Gastrointestinal Agents; Glomerular Fi | 1999 |
1 other study available for midodrine and Hepatitis C
| Article | Year |
|---|---|
Hepatorenal syndrome: are we missing some prognostic factors?
Topics: Albumins; Alcoholism; Autoimmune Diseases; Creatinine; End Stage Liver Disease; Female; Hepatitis C; | 2012 |